Endometrial pathology and estrogens

Zev Rosenwaks; Anne C. Wentz; Georgeanna Seegar Jones; Maria D. Urban; Peter A. Lee; Claude J. Migeon; Tim H. Parmley; J. Donald Woodruff

Endometrial pathology and estrogens

Zev Rosenwaks, Anne C. Wentz, Georgeanna Seegar Jones, Maria D. Urban, Peter A. Lee, Claude J. Migeon, Tim H. Parmley, J. Donald Woodruff

Department of Pediatrics

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Endometrial biopsies were obtained from 46 hypogonadal patients (44 with gonadal dysgenesis; 2 panhypopituitary) who were receiving estrogen-progestogen therapy. Endometrial abnormalities occurred only in patients receiving a total lifetime conjugated estrogen dose of ≥2500 mg and who had received estrogen treatment for a period longer than 4.2 years. The biopsy outcome was significantly related (P<0.01) to the estrogen dose at time of biopsy and to the total lifetime dose (P<0.05). The progestational drugs administered did not protect against development of endometrial abnormalities. None of the abnormal endometrial patterns were associated with abnormal vaginal bleeding.

Original language	English (US)
Pages (from-to)	403-410
Number of pages	8
Journal	Obstetrics and gynecology
Volume	53
Issue number	4
State	Published - Apr 1979

All Science Journal Classification (ASJC) codes

Obstetrics and Gynecology

Cite this

@article{bd70b15172b746c2ab85cad1bfb8774a,

title = "Endometrial pathology and estrogens",

abstract = "Endometrial biopsies were obtained from 46 hypogonadal patients (44 with gonadal dysgenesis; 2 panhypopituitary) who were receiving estrogen-progestogen therapy. Endometrial abnormalities occurred only in patients receiving a total lifetime conjugated estrogen dose of ≥2500 mg and who had received estrogen treatment for a period longer than 4.2 years. The biopsy outcome was significantly related (P<0.01) to the estrogen dose at time of biopsy and to the total lifetime dose (P<0.05). The progestational drugs administered did not protect against development of endometrial abnormalities. None of the abnormal endometrial patterns were associated with abnormal vaginal bleeding.",

author = "Zev Rosenwaks and Wentz, {Anne C.} and Jones, {Georgeanna Seegar} and Urban, {Maria D.} and Lee, {Peter A.} and Migeon, {Claude J.} and Parmley, {Tim H.} and Woodruff, {J. Donald}",

year = "1979",

month = apr,

language = "English (US)",

volume = "53",

pages = "403--410",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Endometrial pathology and estrogens

AU - Rosenwaks, Zev

AU - Wentz, Anne C.

AU - Jones, Georgeanna Seegar

AU - Urban, Maria D.

AU - Lee, Peter A.

AU - Migeon, Claude J.

AU - Parmley, Tim H.

AU - Woodruff, J. Donald

PY - 1979/4

Y1 - 1979/4

N2 - Endometrial biopsies were obtained from 46 hypogonadal patients (44 with gonadal dysgenesis; 2 panhypopituitary) who were receiving estrogen-progestogen therapy. Endometrial abnormalities occurred only in patients receiving a total lifetime conjugated estrogen dose of ≥2500 mg and who had received estrogen treatment for a period longer than 4.2 years. The biopsy outcome was significantly related (P<0.01) to the estrogen dose at time of biopsy and to the total lifetime dose (P<0.05). The progestational drugs administered did not protect against development of endometrial abnormalities. None of the abnormal endometrial patterns were associated with abnormal vaginal bleeding.

AB - Endometrial biopsies were obtained from 46 hypogonadal patients (44 with gonadal dysgenesis; 2 panhypopituitary) who were receiving estrogen-progestogen therapy. Endometrial abnormalities occurred only in patients receiving a total lifetime conjugated estrogen dose of ≥2500 mg and who had received estrogen treatment for a period longer than 4.2 years. The biopsy outcome was significantly related (P<0.01) to the estrogen dose at time of biopsy and to the total lifetime dose (P<0.05). The progestational drugs administered did not protect against development of endometrial abnormalities. None of the abnormal endometrial patterns were associated with abnormal vaginal bleeding.

UR - http://www.scopus.com/inward/record.url?scp=0018383364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018383364&partnerID=8YFLogxK

M3 - Article

C2 - 220573

AN - SCOPUS:0018383364

SN - 0029-7844

VL - 53

SP - 403

EP - 410

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 4

ER -

Endometrial pathology and estrogens

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this